These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33338869)

  • 41. Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.
    Barlaam B; De Savi C; Dishington A; Drew L; Ferguson AD; Ferguson D; Gu C; Hande S; Hassall L; Hawkins J; Hird AW; Holmes J; Lamb ML; Lister AS; McGuire TM; Moore JE; O'Connell N; Patel A; Pike KG; Sarkar U; Shao W; Stead D; Varnes JG; Vasbinder MM; Wang L; Wu L; Xue L; Yang B; Yao T
    J Med Chem; 2021 Oct; 64(20):15189-15213. PubMed ID: 34647738
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A patent review of selective CDK9 inhibitors in treating cancer.
    Wu T; Wu X; Xu Y; Chen R; Wang J; Li Z; Bian J
    Expert Opin Ther Pat; 2023 Apr; 33(4):309-322. PubMed ID: 37128897
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
    Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
    PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
    Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
    Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
    Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
    PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.
    Wang X; Yu C; Wang C; Ma Y; Wang T; Li Y; Huang Z; Zhou M; Sun P; Zheng J; Yang S; Fan Y; Xiang R
    Eur J Med Chem; 2019 Nov; 181():111535. PubMed ID: 31376566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
    McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
    Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
    Beauchamp EM; Abedin SM; Radecki SG; Fischietti M; Arslan AD; Blyth GT; Yang A; Lantz C; Nelson A; Goo YA; Akpan I; Eklund EA; Frankfurt O; Fish EN; Thomas PM; Altman JK; Platanias LC
    Blood; 2019 Mar; 133(11):1171-1185. PubMed ID: 30587525
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of HyT-Based Degraders of CDK9-Cyclin T1 Complex.
    Lin R; Yang J; Liu T; Wang M; Ke C; Luo C; Lin J; Li J; Lin H
    Chem Biodivers; 2023 Aug; 20(8):e202300769. PubMed ID: 37349855
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments.
    Xiao L; Liu Y; Chen H; Shen L
    Cancer Biol Ther; 2023 Dec; 24(1):2219470. PubMed ID: 37272701
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia.
    Zhang H; Huang J; Chen R; Cai H; Chen Y; He S; Xu J; Zhang J; Wang L
    Bioorg Med Chem; 2022 Oct; 72():116994. PubMed ID: 36087428
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells.
    Cao S; Yu Y; Chen S; Lei D; Wang S; Pan X; Peng J
    Biochem Biophys Res Commun; 2017 Jan; 482(4):536-541. PubMed ID: 27847320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.
    Zhou H; Bai L; Xu R; Zhao Y; Chen J; McEachern D; Chinnaswamy K; Wen B; Dai L; Kumar P; Yang CY; Liu Z; Wang M; Liu L; Meagher JL; Yi H; Sun D; Stuckey JA; Wang S
    J Med Chem; 2019 Dec; 62(24):11280-11300. PubMed ID: 31747516
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer.
    Chen W; Wu Y; Yang C; Ren W; Hou L; Liang H; Wu T; Kong Y; Wu J; Rao Y; Chen C
    Biomed Pharmacother; 2024 Aug; 177():116972. PubMed ID: 38906024
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs.
    Zeng Y; Xiao J; Xu Y; Wei F; Tian L; Gao Y; Chen Y; Hu Y
    J Med Chem; 2023 Sep; 66(18):12877-12893. PubMed ID: 37671907
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer.
    Lücking U; Scholz A; Lienau P; Siemeister G; Kosemund D; Bohlmann R; Briem H; Terebesi I; Meyer K; Prelle K; Denner K; Bömer U; Schäfer M; Eis K; Valencia R; Ince S; von Nussbaum F; Mumberg D; Ziegelbauer K; Klebl B; Choidas A; Nussbaumer P; Baumann M; Schultz-Fademrecht C; Rühter G; Eickhoff J; Brands M
    ChemMedChem; 2017 Nov; 12(21):1776-1793. PubMed ID: 28961375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel, selective CDK9 inhibitors for the treatment of HIV infection.
    Németh G; Varga Z; Greff Z; Bencze G; Sipos A; Szántai-Kis C; Baska F; Gyuris A; Kelemenics K; Szathmáry Z; Minárovits J; Kéri G; Orfi L
    Curr Med Chem; 2011; 18(3):342-58. PubMed ID: 21143121
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.
    Xu Z; Zhang B; Liu Z; Gou S
    Eur J Med Chem; 2022 Dec; 244():114875. PubMed ID: 36332552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.